<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565069</url>
  </required_header>
  <id_info>
    <org_study_id>FIND-EU - CF163</org_study_id>
    <nct_id>NCT02565069</nct_id>
  </id_info>
  <brief_title>Identification for the Treatment of Complex Arrhythmias</brief_title>
  <official_title>Identification for the Treatment of Complex Arrhythmias (CartoFinder™ Algorithm Trial: &quot;CF163 EU&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this trial is to demonstrate that the utilization of CartoFinder™ 4D&#xD;
      Local Activation Time (LAT) Algorithm may help identify and improve the outcome for the&#xD;
      treatment of complex arrhythmias.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1, 2015</start_date>
  <completion_date type="Actual">January 24, 2018</completion_date>
  <primary_completion_date type="Actual">January 24, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identify rate of slowing for the overall mean atrial fibrillation rate</measure>
    <time_frame>Day 0 (procedure date)</time_frame>
    <description>Identify rate of slowing for the overall mean atrial fibrillation rate that can be achieved by using CARTOFINDER™ 4D LAT Algorithm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate Freedom from procedure-related primary adverse events</measure>
    <time_frame>7 days</time_frame>
    <description>Evaluate Freedom from procedure-related primary adverse events at 7 days post-procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate procedural results</measure>
    <time_frame>Day 0 (procedure date)</time_frame>
    <description>Proportion of subjects with focal impulses / Repetitive Activation Pattern (RAP)s and number of areas and locations of focal impulses / RAPs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate procedural results</measure>
    <time_frame>Day 0 (procedure date)</time_frame>
    <description>Proportion of subjects with Normal Sinus Rhythm (NSR) after CF guided ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate procedural results</measure>
    <time_frame>Day 0 (procedure date)</time_frame>
    <description>Proportion of subjects with AF organization after CF guided ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate procedural results</measure>
    <time_frame>Day 0 (procedure date)</time_frame>
    <description>Proportion of subjects with acute procedural success, i.e. subjects with spontaneous return to NSR or AF organization after CF guided ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate freedom from documented recurrence of atrial fibrillation</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Evaluate freedom from documented recurrence of atrial fibrillation at 6 and 12 months post-procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Arrhythmias</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of CartoFinder™ device with CARTO® 3 System V5 Navigation to treat complex arrhythmias</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CartoFinder™ Device with CARTO® 3 System V5 Navigation</intervention_name>
    <description>Ablation treatment</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Signed the Patient Informed Consent Form (ICF)&#xD;
&#xD;
          3. Scheduled to undergo a clinically-indicated catheter ablation procedure for treatment&#xD;
             of&#xD;
&#xD;
               -  Persistent atrial fibrillation (defined as continuous atrial fibrillation that is&#xD;
                  sustained beyond seven consecutive days).&#xD;
&#xD;
               -  Drug-resistant Atrial Fibrillation. (failed 1 or more class I or III&#xD;
                  antiarrhythmic drugs) and demonstrating Persistent AF (requiring drugs or&#xD;
                  electrical shock to terminate)&#xD;
&#xD;
               -  Persistent AF despite prior conventional ablation.&#xD;
&#xD;
          4. Previous procedure permitted but limited to single Pulmonary Vein Isolation (PVI).&#xD;
&#xD;
          5. In AF at the time of the Pre-CartoFinder Map (spontaneous or induced)&#xD;
&#xD;
          6. Able and willing to comply with all pre-, post-, and follow-up testing and&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Paroxysmal Atrial Fibrillation&#xD;
&#xD;
          2. Continuous AF &gt; 12 months (1-Year) (Longstanding Persistent AF)&#xD;
&#xD;
          3. Cardioversion refractory (The inability to restore sinus rhythm for 30 secs or longer&#xD;
             following electrical cardioversion. If a patient does not have documented evidence of&#xD;
             being successfully cardioverted (Normal Sinus Rhythm (NSR) &gt; 30 secs), the patient&#xD;
             must be cardioverted prior to the ablation procedure. Failure to cardiovert based on&#xD;
             the above criteria is considered a screen failure.&#xD;
&#xD;
          4. A complex arrhythmia secondary to a reversible or non-cardiac cause. For example: a&#xD;
             complex arrhythmia secondary to electrolyte imbalance or thyroid disease.&#xD;
&#xD;
          5. Left atrial size &gt;55 mm (echocardiography, parasternal long axis view).&#xD;
&#xD;
          6. Significant congenital anomaly or medical problem that in the opinion of the&#xD;
             investigator would preclude enrollment in this study.&#xD;
&#xD;
          7. Structural atrial disease such as a prior history of atriotomy from prior atrial&#xD;
             surgery, presence of an atrial septal defect, and/or presence of an atrial septal&#xD;
             closure patch.&#xD;
&#xD;
          8. History of or current blood clotting or bleeding abnormalities, contraindication to&#xD;
             systemic anticoagulation (i.e., heparin, warfarin, dabigatran, or a direct thrombin&#xD;
             inhibitor), significant pulmonary disease, cardiac surgeries, unstable angina,&#xD;
             uncontrolled heart failure, acute illness or systemic infection, or any other disease&#xD;
             or malfunction that would preclude treatment in the opinion of the investigator.&#xD;
&#xD;
          9. Enrollment in an experimental study evaluating another device or drug under&#xD;
             investigation.&#xD;
&#xD;
         10. Prosthetic valve&#xD;
&#xD;
         11. Presence of intramural thrombus, tumor or other abnormality / condition that precludes&#xD;
             vascular access, catheter introduction or manipulation.&#xD;
&#xD;
         12. Women of child bearing potential whom are pregnant, lactating, or planning to become&#xD;
             pregnant during the course of the trial.&#xD;
&#xD;
         13. Presenting contra-indications for the devices used in the study, as indicated in the&#xD;
             respective Instructions For Use.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis (AZ) Sint Jan Brugge</name>
      <address>
        <city>Ruddershove</city>
        <state>Brugge</state>
        <zip>10 - 8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis A ntwerpen (UZA)</name>
      <address>
        <city>Wilrijkstraat</city>
        <state>Edegem</state>
        <zip>10 - 2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenhuis (OLV) Hospital</name>
      <address>
        <city>Aalst</city>
        <state>Moorselbaan</state>
        <zip>164 - 9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>České Budějovice Hospital</name>
      <address>
        <city>České Budějovice</city>
        <state>Němcové</state>
        <zip>585/54 - 370 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

